Liver fibrosis and therapeutic strategies: The goal for improving metabolism

Current Drug Targets

Volumn 10, Issue 6, 2009, Pages 505-512

  Balsano, Claro ^a   Alisi, Anna ^b   Nobili, Valerio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

HCV; Hepatic fibrosis; Insulin resistance; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

GLITAZONE DERIVATIVE; INTERFERON; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DRUG STRUCTURE; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS B; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER METABOLISM; LIVER PROTECTION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVIEW; RISK FACTOR; STELLATE CELL; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; FATTY LIVER; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 68349125150     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009788488459     Document Type: Review

References (116)

1. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257-5.
2. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493-503.
3. Blonsky JJ, Harrison SA. Review article: nonalcoholic fatty liver disease and hepatitis C virus - partners in crime. Aliment Pharmacol Ther 2008; 27: 855-65.
4. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48(Suppl 1): S104-12.
5. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128: 837-47.
6. Alisi A, Nobili V. Molecular genetics of NASH: the role of polymorphisms. J Hepatol 2007; 47: 868-9.
7. Manco M, Marcellini M, Nobili V. Lifestyle advice in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22: 604-5.
8. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16, vii.
9. Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med 2008; 19: 75-82.
10. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2 Suppl 1): S99-112.
11. World Health Organisation. Initiative for vaccine research (IVR); hepatitis C page. Available at: http://www.who.int/vaccine_research/ diseases/viral_cancers. Accessed January 15, 2008.
12. Asselah T, Rubbia-Brandt L, Marcellin P, Negro, F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123-30.
13. Negro F. Steatosis in chronic hepatitis C: friend or foe? Liver Int 2008; 28: 294-6.
14. Thomopoulos KC, Arvaniti V, Tsamantas AC, Dimitropoulou D, Gogos CA, Siagris D, et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006; 18: 233-7.
15. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
16. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408-14.
17. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-36.
18. Younossi Z, McCullough A, Ong JP, Barnes DS, Post A, Tavill A, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 3 8: 1-5.
19. Sanyal AJ. Review article: non-alcoholic fatty liver disease and hepatitis C - risk factors and clinical implications. Aliment Pharmacol Ther 2005; 22(Suppl 2): 48-51.
20. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-9.
21. Preiss D, Sattar. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. N Clin Sci (Lond) 2008; 115: 141-50.
22. Torres DM, Harrison SA. Current treatments in nonalcoholic steatohepatitis. Curr Treat Options Gastroenterol 2007; 10: 425-34.
23. Dixon JB. Surgical treatment for obesity and its impact on nonalcoholic steatohepatitis. Clin Liver Dis 2007; 11: 141-54, ix-x.
24. Iimuro Y, Brenner DA. Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res 2008; 25: 249-58.
25. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.
26. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22(Suppl 1): S79-84.
27. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
28. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 2007; 11: 1031-51.
29. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Digest Liver Dis 2004; 36: 231-42.
30. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-9.
31. Nonomura A, Enomoto Y, Takeda M, Tamura T, Kasai T, Yoshikawa T, et al. Clinical and pathological features of non-alcoholic steatohepatitis. Hepatol Res 2005; 33: 116-21.
32. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 68-71.
33. Day CP. NASH-related liver failure: one hit too many? Am J Gastroenterol 2002; 97: 1872-4.
34. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006; 26: 1021-8.
35. dela Pena A, Leclercq I, Field J, Gorge J, Jones B, Farrell G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005; 129: 1663-74.
36. Marchesini G, Bugianesi E, Forlani G, Cerrelli, F; Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
37. Bedogni G, Miglioli L. Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
38. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol 2006; 54: 229-39.
39. Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr. Gastroenterol Rep 2008; 10: 73-80.
40. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509-18.
41. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
42. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J. Gastroenterol 2008; 14: 185-92.
43. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000.
44. Bonora E, Kiechl S, Willeit J, Oberhollenzer F. Egger G, Bonadonna RC, et al. Metabolic Syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes 2003; 27: 1283-9.
45. Manco M, Bedogni G. Marcellini M, Devito R, Ciampalini P, Sartorelli MR, et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis Gut 2008; 57: 1283-87.
46. Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 1222-4.
47. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007; 102: 399-408.
48. Petruzzelli M, Lo Sasso G, Portincasa P, Palasciano G, Moschetta A. Targeting the liver in the metabolic syndrome: evidence from animal models. Curr Pharm Des 2007; 13: 2199-207.
49. Kraegen EW, Cooney GJ. Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 2008; 19: 235-41.
50. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50; 1844-50.
51. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with nonalcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-42.
52. Carmiel-Haggai M, Cederbaum AI, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 2005; 19: 136-38.
53. Wilfred de Alwis NM, Day CP. Genes and nonalcoholic fatty liver disease. Curr Diab Rep 2008; 8: 156-63.
54. van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis 2008; 12(4): 805-24, ix.
55. Guo JS, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis 2007; 27: 413-26.
56. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42: 5-13.
57. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661-9.
58. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB 2002, 16: 185-94.
59. Sabile A, Perlemuter G, Bono F, Kohara K, Demaugre F, Kohara M, et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 1999; 30: 1064-76.
60. Tsutsumi, T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002; 35: 937-46.
61. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2002; 33: 106-15.
62. Castéra L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53: 420-4.
63. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-72.
64. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
65. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198-206.
66. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41: 82-7.
67. Clouston AD, Jonsson JR, Powell EE, Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis 2007; 11: 173-89.
68. Ratziu V, Munteanu M, Charlotte, F, Bonyhay L, Poynard T, LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 1049-55.
69. Romero-Gómez M, Castellano-Megias VM, Grande L, Irles JA, Cruz M, Nogales MC, Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003; 98: 1135-41.
70. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005; 166: 1655-69.
71. Sung CK, She H, Xiong S, Tsukamoto H. Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells.Am. J. Physiol. Gastrointest. Liver Physiol 2004; 286: G722-9.
72. El-Zayadi AR, Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol 2008; 14: 4120-6.
73. Amarapurkar D, Das HS, Chronic liver disease in diabetes mellitus. Trop Gastroenterol 2002; 23: 3-5.
74. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection Diabetes Care 2006; 29: 2462-6.
75. Behrendt CE, Ruiz RB. Hyperglycemia among persons with hepatitis C: not the classical diabetic phenotype. Diabetes Res Clin Pract 2006; 71: 68-74.
76. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol 2004; 40: 484-90.
77. Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003; 52: 1638-43.
78. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease Hepatology 2006; 44: 27-33.
79. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson, JR, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004; 39: 1230-8.
80. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J. Hepatol 2003; 39: 1042-8.
81. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-44.
82. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40: 1078-87.
83. Balsano C, Alisi A. Hepatitis C virus (HCV): an RNA virus with a pro-oncogenic potential. Dig Liver Dis 2007; 39(Suppl 1): S46-51.
84. Sanyal A, Contos M, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003; 98: 2064-71.
85. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
86. Blonsky JJ, Harrison SA. Review article: nonalcoholic fatty liver disease and hepatitis C virus - partners in crime. Aliment Pharmacol Ther 2008; 27: 855-865.
87. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006; 24: 1349-57.
88. Petta S, Cammà C, Marco VD, Alessi N, Cabibi D, Caldarella R, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103: 1136-44.
89. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
90. Cheung O, Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis 2008; 12: 573-585.
91. Sterling RK, Contos MJ, Smith PG, Stravitz, RT, Luketic VA, Fuchs M, et al. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008; 47: 1118-27.
92. Negro F. Insulin resistance and HCV: will new knowledge modify clinical management? J Hepatol 2006; 45: 514-9.
93. Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Oza N, Nakashita S, et al. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int 2009; 29: 213-20.
94. Bondini S, Younossi ZM. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol 2006; 52: 135-43.
95. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut 2000; 46: 443-6.
96. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 2007; 22(Suppl 1): S73-8.
97. Zardi EM, Dobrina A, Ambrosino G, Margotta D, Polistina F, Afeltra A. New therapeutic approaches to liver fibrosis: a practicable route? Curr Med Chem 2008; 15: 1628-44.
98. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32.
99. Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindström J, Tuomilehto J, et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 2003; 52: 2532-8.
100. Thomas EL, Brynes AE, Hamilton G, Patel N, Spong A, Goldin RD, et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 5813-9.
101. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004; 20: 623-8.
102. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003; 12: 189-92.
103. Buchwald H, Williams SE. Bariatric surgery worldwide 2003. Obes Surg 2004; 14: 1157-64.
104. Kadayifci A, Merriman RB, Bass NM. Medical treatment of nonalcoholic steatohepatitis. Clin Liver Dis 2007; 11: 119-40, ix.
105. Khashab M, Chalasani N. Use of insulin sensitizers in NASH. Endocrinol Metab Clin North Am 2007; 36: 1067-87.
106. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.
107. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
108. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.
109. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008; 57: 306-14.
110. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
111. Solomon SS, Usdan LS, Palazzolo MR. Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s). Am J Med Sci 2001; 322: 75-8.
112. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005; 21: 871-9.
113. Uygun A, Kadayifci A, Isik AT, Ozgurtas T.; Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-44.
114. Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008; 30: 1168-76.
115. Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007; 14: 29-35.
116. Solis-Herruzo JA, Pérez-Carreras M, Rivas E, Fernández-Vázquez I, Garfia C, Bernardos E, et al. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 2005; 100: 1091-8.